Patients with #cancer who are #sarcopenic likely have significant #eGFR overestimation. Here we found that sarcopenia is associated with widely discrepant eGFR-creatinine and eGFR-cystatin C in a large cohort of patients who underwent body comp analysis.

doi.org/10.1002/jcsm.1…

David Leaf
AnIpB
Don Chute
Shveta Motwani
Matthew Abramson
Wenxin (Vincent) Xu
Kerry Reynolds
Kenar Jhaveri
Jamie Hirsch
meg sise
MGH Onconephrology
@kartiksehgal_md

🧵1/ Cisplatin has been a cancer-fighting drug for over 50 years, but it comes with a significant risk: #AKI . Let’s dive into cisplatin-associated AKI (CP-AKI). #Cisplatin #Onconephrology American Society of Onconephrology

A risk score for cisplatin-induced AKI. Next let's test prevention in high risk patients!

bmj.com/content/384/bm…

MGH Onconephrology Shruti Gupta David Leaf

AKI and CKD risks are increased in cancer survivors receiving BRAF for melanoma.
academic.oup.com/ndt/advance-ar…

MGH Onconephrology Kavita Mistry

🚨 New publication alert! Paul E. Hanna, MD MSc @Shrutigkidney KIReports #Cardiooncology #Onconephrology .. Ever wondered the risk factors for developing most clinically-relevant forms of hypertension & proteinuria in adult patients with cancer receiving VSPIs? Let’s delve in…

Pitfalls on TLS diagnostic criteria Edgar V. Lerma 🇵🇭 Naji Alhamid BT Workeneh Tiffany Caza

Association of PPI Use and Immune Checkpoint Inhibitor Mediated Acute Kidney Injury: A Meta-Analysis and a Review of Related Outcomes | AJN ⁦Arjun Mohan⁩ ⁦Wisit Cheungpasitporn MD FACP | FASN | FAST⁩ ⁦⁦Mayo Clinic Nephrology⁩ ⁦Swetha Kanduri⁩ karger.com/ajn/article/do…

#TeamSise Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma | Nephrology Dialysis Transplantation ⁦Kavita Mistry⁩ ⁦Emma Qiyu Wang⁩ ⁦Paul E. Hanna, MD MSc⁩ ⁦meg sise⁩ academic.oup.com/ndt/advance-ar…

docwirenews.com/post/estimatin…

Transient acute kidney injury after Chimeric Antigen Receptor T-cell therapy in patients with hematological malignancies | ⁦CKJ⁩ academic.oup.com/ckj/advance-ar…

Such a pleasure discussing our research on eGFR discrepancies in patients with cancer! Medical College of Wisconsin MCW Cancer Center MCW IM Chief Residents Froedtert MGH Onconephrology

The pathophysiology of cisplatin nephrotoxicity go.nature.com/3D7993E

MCW Nephrology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance | Nature Reviews Clinical Oncology nature.com/articles/s4157…

Emerging trends in Onconephrology 2024 edition Prakash Gudsoorkar MCW Nephrology ASN Kidney News

Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review | Nephrology | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…

glad to be part of this energetic group leading American Society of Onconephrology MCW Nephrology MGH Onconephrology

Related articles for the cover:

Predictive Model for Kidney Failure After Kidney Cancer by Oksana Harasemiw et al: bit.ly/46L5J3e

Onconephrology Core Curriculum by Niloufar Yarandi & Anushree Shirali: bit.ly/3Ss5K7y

Thanks to Ed Intern Dilushi Wijayaratne:

In NEJM Group's final report on #KidneyWk , our clinician-guides, meg sise and Opeyemi Olabisi, share key takeaways from the nephrology meeting and how these findings might change their practice. jwat.ch/40r4XWx